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Immunopathologic studies (1) in humans and experimental animals have
established that deposition and/or in situ formation of immune complexes
mediate most forms of glomerular injury. In spite of numerous reports of
treatments of idiopathic immune complex glomerulonephritis in humans and
experimental glomerulonephritis in animals, results with the more traditional
approaches have generally been unsatisfactory. Recently, dissociation ofimmune
deposits from glomeruli by administration of excess antigen (2-5) or anti-Ig (6)
has been more successful. A role for complement in redistribution and clearance
of immune complexes from glomeruli has also been explored (7), with results
suggesting that the deposits are not static once formed; this knowledge has not
yet been exploited therapeutically.
As a generalized, nonspecific modality, we hypothesized that exogenous pro-
teases should be capable ofremoving glomerular immune deposits . To test this
idea, we chose to study passive Heymann nephritis (PHN),' a widely used
experimental model in rats that closely resembles human membranous nephrop-
athy. Insight into the pathogenesis of Heymann nephritis has been greatly
advanced in recent years, and direct binding of antibody to fixed glomerular
antigen is now considered to be the principal mechanism ofsubepithelial immune
deposit formation (8, 9). The responsible antigen appears to be a 330-kD
glycoprotein of proximal tubular epithelial brush border membranes which is
also present on glomerular epithelial podocytes (10, 11). Tissue injury is thought
to result from activation of complement without involving inflammatory cells
(12).
PHN has other features that make it an attractive model system . Injection of
heteroantibody specific for a glomerular antigen leads to accumulation in glo-
meruli, and after 3-6 d the deposited antibody may induce transientproteinuria.
Since the culprit Ig is from a different animal species, this proteinuria is referred
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to as the heterologous phase of the disease. By 7-10 d, the recipient animal
usually develops an immune response to the heterologous Ig. The resulting
autologous antibody binds to the heteroantibody still present in the glomeruli,
thereby inciting a new phase of glomerulonephritis, termed autologous because
it is caused by host antibody. The autologous phase is typically more pronounced
and persistent than the heterologus phase . This biphasic character of glomerular
immune complex formation makes PHN particularly well adapted for study at
multiple time points. The effects of removal of heteroantibody before onset of
the autologous phase and the effects of treatment during or after development
of the autologous phase can be studied independently simply by intervening at
different times after injection of the heteroantibody .
In the present study, we treated PHN with proteolytic enzymes at different
phases of the disease and examined the effects on glomerular immune complexes
and urinary protein excretion . The results show that exogenous enzymes can
prevent or remove glomerular immune complex deposits and decrease protein-
uria.
Materials and Methods
Animals.
￿
Male Sprague Dawley rats weighing 250 g were obtained from Zivic Miller
(Allison Park, PA).
Induction of PHN.
￿
FxIA tubular antigen was prepared from Sprague Dawley renal
cortices (13). New Zealand white rabbits were immunized with 10 mg of fraction LA of
renal cortical brush border membranes (FxIA) in CFA (Difco Laboratories Inc., Detroit,
MI) in the rear footpads. 2 wk later, a booster immunization with the same preparation
was given in multiple subcutaneous sites and repeated biweekly. Rabbits were periodically
bled and we assessed antibody against tubular antigen by indirect immunofluorescence.
Antiserum against FxIA was heat inactivated (56°C, 30 min) and absorbed with 0.1 ml
normal rat serum, and subsequently, 1 ml packed rat blood cells per ml antiserum. The
IgG fraction of the rabbit antiserum was prepared by precipitation with half-saturated
(NH4)2SO4 followed by DEAE-cellulose column chromatography in 0.0175 M potassium
phosphate buffer, pH 6.30. This preparation is referred to as Heymann antibody; its
specificity was confirmed by indirect immunofluorescence. To induce PHN, it was given
by tail vein.
Experimental Design.
￿
Six groups of animals were studied so that doses of Heymann
antibody could be varied and protease treatment could be instituted at different phases
of the disease (Table 1).
GroupA, rats were randomly divided into two subgroups after receiving 5 mg Heymann
antibody on day 1 . Rats in subgroup 1 were treated with 2 .5 ml of a mixture of
chymopapain (1 mg/ml) and subtilisin BPN' (0.5 mg/ml; Sigma Chemical Co., St. Louis,
MO) in PBS, pH 7 .4, given intraperitoneally twice daily from days 1-7 ; control rats
(subgroup 2) were given corresponding injections of 2.5 ml normal saline. Animals were
killed on day 12.
Group B, rats received 10 mg Heymann antibody intravenously on day 1, and were
randomly subdivided. Subgroup 1 rats were treated with chymopapain and subtilisin twice
daily on days 1-5 as above, and control rats (subgroup 2) were treated with saline instead
of protease. Animals were killed on day 5.
Group C, rats received 10 mg Heymann antibody. Protease (subgroup 1) or saline
(subgroup 2) injections were begun on day 6 and continued until they were killed on day
12 .
Group D, after 60 mg of Heymann antibody was given as three 20-mg injections at 1-
h intervals, rats were allocated randomly to four subgroups. Subgroup I rats were given
protease on days 1-7, subgroup 2 rats on days 6-12, and subgroup 3 rats on days 6-18 .
Control rats (subgroup 4) did not receive any treatment. Rats were killed on day 18.NAKAZAWA ET AL.
TABLE I
Experimental Design for Induction and Treatment of
Passive Heymann Nephritis
* Number of animals.
t IgG fraction of rabbit anti-FxIA antiserum given on day 1.
Chymopapain plus subtilisin.
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Group E, 15 d after administration of 40 mg Heymann antibody given as two 20-mg
injections 1 h apart, rats were randomly divided into protease-treated and control groups.
Enzyme treatment was started on day 15 and continued through day 25, when all animals
were killed .
Group F, to assess possible toxicity of protease treatment in normal rats, animals were
randomly divided into six subgroups. Subgroup 1 rats received enzymes intraperitoneally
as above on days 1-5, and were killed on day 5; rats in subgroup 2 received enzymes
intraperitoneally on days 1-12, and were killed on day 12; subgroup 3 received saline
intraperitoneally on days 1-5, and were killed on day 5; subgroup 4 rats received saline
intraperitoneally on days 1-12, and were killed on day 12; rats in subgroups 5 and 6 did
not receive any treatment and were killed on days 5 and 12, respectively.
Morphology.
￿
Renal tissue obtained at sacrifice was processed for light, immunofluores-
cence, and electron microscopy (14). For light microscopy, after fixation in 10% neutral
formalin, sections of paraffin-embedded tissue cut at 2 Am were stained with H and E and
periodic acid-silver methenamine.
For immunofluorescence microscopy, blocks of renal cortex were snap-frozen in chilled
2-methylbutane suspended in liquid nitrogen and stored at -70 °C. Cryostat sections, 4
Am, were fixed in acetone for 1 min, washed in PBS, incubated in a moist chamber with
antiserum, washed in PBS, and mounted in glycerol-PBS. Triplicate sections were reacted
with fluorescein-conjugated goat antibody against rabbit IgG (Miles Laboratories Inc.,
Naperville, IL), rhodamine-conjugated goat antibody to rat IgG (United States Biochem-
ical Corp., Cleveland, OH) and fluorescein-conjugated goat anti-rat C3 (United States
Biochemical Corp.); all antisera were diluted 1 :10. Coded slides were examined in a
fluorescence microscope (E. Leitz, Inc., Wetzlar, Federal Republic of Germany) inde-
pendently by two observers, and the intensity of staining was scored as - to 2+. In the
Group n*
Hey-
mann
antibody
(mg)t
Treatment Days of
treatment
Day
killed
A1 16 5 Protease$ 1-7 12
2 19 5 Saline 1-7 12
B1 12 10 Protease 1-5 5
2 12 10 Saline 1-5 5
C1 12 10 Protease 6-12 12
2 13 10 Saline 6-12 12
D1 7 60 Protease 1-7 18
2 8 60 Protease 6-12 18
3 6 60 Protease 6-18 18
4 11 60 - - 18
El 10 40 Protease 15-25 25
2 8 40 - - 25
171 6 0 Protease 1-5 5
2 6 0 Protease 1-12 12
3 6 0 Saline 1-5 5
4 6 0 Saline 1-12 12
5 6 0 - - 5
6 6 0 - - 12197 6 GLOMERULAR IMMUNE COMPLEX AND PROTEINURIA REDUCTION
TABLE 11
Immune Deposits in Glomeruli of Rats Injected with 5 or 10 mg Heymann Antibody and
Treated with Protease
* Subgroup 1 rats received protease; subgroup 2 rats received saline.
t Number of animals.
￿
-
§ Data are number of rats positive for each immune reactant at the intensity indicated.
occasional instance when the scores from the two observers differed, the section was
reexamined by both observers and a score was agreed upon before decoding.
For electron microscopy, 0.5-mm3 blocks were fixed in 2.5% glutaraldehyde in caco-
dylate buffer, pH 7.4, postfixed in 1 % Os04, stained en-bloc in uranyl acetate, dehydrated,
and embedded in Spurr's epoxy. Sections from three randomly selected rats from each
subgroup were evaluated in a 201C electron microscope (Philips Electronic Instruments,
Inc., Mahwah, NJ). The number and size of electron dense deposits in subendothelial,
intramembranous, subepithelial, and mesangial glomerular sites were determined by
planimetry with a computerized morphometry system (Bioquant, R & M Biometrics, Inc .,
Nashville, TN). The data were normalized to the length of basement membrane studied
for each specimen.
Urine Studies.
￿
24-h urine collections were done on individual rats in metabolic cages
without food but with free access to water. Urine was collected under 0.5 ml mineral oil
and centrifuged at 2,000 rpm for 20 min at 4°C. Supernatants were stored at -20 ° C
until tested. Protein content was determined by precipitation in 3% sulfosalicylic acid
(15).
Antibody Response to Heterologous Protein.
￿
Before sacrifice, blood was drawn from the
aorta, and serum was obtained and frozen at -70 ° C until tested. For measurement of
antibody levels against rabbit IgG, we used ELISA (16). 96-well polystyrene flat-bottomed
microtiter plates (Flow Laboratories, Inc., McLean, VA) were coated with 100,ul/well of
normal rabbit IgG (1 Ag/ml in 0.1 M sodium carbonate, pH 9.4) at 37°C for 16 h. After
coating and between all subsequent steps, wells were washed three times with PBS. The
coated plates were blocked by incubation with 1 % BSA (Sigma Chemical Co.) in PBS at
37 °C for 1 h. Serum samples, in serial twofold dilutions, were added (100 ul/well) and
incubated for I h at room temperature. The plates were then incubated for 1 h at room
temperature with alkaline phosphatase-conjugated goat anti-rat IgG (Cappel Laborato-
ries, Cochranville, PA) diluted 1 :100 in PBS. The chromogenic substrate p-nitrophenyl
disodium phosphate (Sigma Chemical Co.) was added at 4 mg/ml in glycine/MgC12 buffer,
pH 10 .5. After 180 min, optical densities were measured at 410 nm in a microplate
reader (Dynatech Laboratories, Inc., Alexandria, VA).
Serum Creatinine.
￿
Serum creatinine was measured by the picric acid method (17).
Results
Morphological Studies. Table II gives the immunofluorescence results for
rabbit IgG (the injected heterologous Heymann antibody), rat IgG (autologous
antibody to the injected rabbit IgG), and rat C3 in groups A, B, and C (see Table
Grade of glomerular immunofluorescence§
Group* nt
Heymann
antibody in-
jected (mg)
Rabbit IgG
1+ 2+ -
Rat IgG
1+ 2+
Rat
-
C3
+
Al 16 5 10 6 0 11 5 0 16 0
2 19 5 2 17 0 2 17 0 17 2
B1 12 10 8 4 0 7 5 0 12 0
2 12 10 3 9 0 7 5 0 12 0
C1 12 10 4 2 6 5 3 4 12 0
2 13 10 0 5 8 0 6 7 13 0NAKAZAWA ET AL.
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I). Granular deposits of both rabbit and rat IgG along the glomerular capillary
loops, characteristic of PHN, were seen in 17 of 19 rats in the control animals
of group A2. On the other hand, only 6 of 16 rats treated with enzymes on days
1-7 (group A1) were positive for rabbit IgG (X2 = 10.4, p <0.01), and only 5 of
16 were positive for rat IgG (X2 = 12.6, p <0.001) at the time of sacrifice. In
rats given 10 mg of Heymann antibody, treated on days 1-5, and killed in the
heterologous phase on day 5 (group B), only 4 of 12 protease-treated rats were
positive for rabbit IgG compared with 9 of 12 saline-treated rats (X2 = 4.2,
p <0.05); there was no difference in frequency ofpositivity forrat IgG. However,
after the same 10-mg dose of Heymann antibody, when we began protease
treatment later (on day 6) and continued until day 12, significantly fewer rats in
the enzyme-treated group had deposits ofrabbit and rat IgG; 4 of 12 protease
treated rats (group C1) had no rabbit IgG compared with 0 of 13 controls (group
C2) (X2 = 5.16, p <0.025), and 5 of 12 protease treated rats had no deposits of
rat IgG compared with 0 of 13 controls (X2 = 6.77, p <0.01) (Fig. 1). There
were no deposits of C3 in rats given 5 or 10 mg of Heymann antibody (groups
A, B, and C), except for two rats in group A.
When larger (40-60 mg) doses of Heymann antibody (Table I, groups D and
E) sufficient to induce proteinuria, i. e., "nephritogenic" doses, were injected, all
animals were positive for both rabbit and rat IgG; the intensity of immunofluo-
rescence in control rats, while somewhat greater than in enzyme-treated rats,
was not significantly different (data not shown). Positivity for rat C3 was 8 of 21
(38%) in protease-treated vs. 8 of 11 (73%) in control rats, which approaches
significance (X2 = 3.5, p <0.1). In the group F1 and F2 controls given protease
but not Heymann antibody (Table I), none showed immunofluorescence for
rabbit IgG, rat IgG, or rat C3.
By electron microscopy, all rats given Heymann antibody had electron dense
deposits in the subepithelial layer of the capillary basement membrane; intra-
membranous and paramesangial deposits were seen rarely, <1% ofall deposits;
we did not see any subendothelial and mesangial deposits. As shown in Table
111, in all groups studied, rats treated with protease had significantly fewer
deposits per unit basement membrane length than the corresponding controls
given saline (all groups, p <0.01) (see also Fig. 2). Among rats given subnephri-
togenic doses of Heymann antibody (5 or 10 mg), the deposits were small and
scattered, and we made no attempt to measure their area. However, in group D
rats given 60 mg of Heymann antibody, a dose resulting in proteinuria (see
below), the deposits were larger and their areas were quantified. Sizes of the
deposits were variable, and there was no significant difference in mean size in
protease-treated (0.050 ± 0.051) and saline-treated (0.036 ± 0.045) rats. Total
cross-sectional area of the deposits per unit basement membrane length, which
is dependent on both size and number of deposits, was significantly less in
protease-treated rats (15.7 ± 1 .87 nm) than in controls (28.6 ± 1.68 nm, p <
0.001). The deposits remaining in protease-treated rats were subjectively less
dense.
By routine light microscopy, group D and E rats (Table I) given 60 and 40 mg
of Heymann antibody had rare epimembranous spikes and deposits, indicative
ofa membranous nephropathy. There were no differences between the protease-1978 GLOMERULAR IMMUNE COMPLEX AND PROTEINURIA REDUCTION
FIGURE 1 .
￿
Immunofluorescence micrographs of glomeruli from group C rats given 10 mg
Heymann antibody on day 1, treated with protease (A and C) or saline (B and D) on days 6-
12, and killed on day 12 . Sections from protease-treated rats stained for heterologous rabbit
IgG showed weaker fluorescence (A) than did untreated controls (B) . Sections from protease-
treated rats stained for autologous rat IgG likewise revealed weaker fluorescence (C) than
controls (D) . The A and B, and Cand D pairs were exposed for the identical times . X 430 .
treated rats and controls in either group . Light microscopy showed no abnor-
malities in the other groups, which received less Heymann antibody .
Urine Studies .
￿
No rat in groups A, B, and C, given low doses of Heymann
antibody, developed proteinuria in either the heterologous phase (day 4-5) or
the autologous phase (day 1 I-12) ofPHN . 24-h urine protein excretions in rats
given 60 mg Heymann antibody (group D) are shown in Fig . 3. Normal male
Sprague Dawley rats weighing 250 g excreted <6 mg protein in 24 h. During
the heterologous phase ofPHN (day 4-5), no subgroup (DI-D4) had significant
proteinuria. Control rats (group D4) given Heymann antibody but not treated
with enzymes developed significant proteinuria by day 11-12, i . e., in the
autologous phase, which increased with time . The mean urine protein excretionsNAKAZAWA ET AL.
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TABLE III
Morphometric Analysis ofElectron Microscopic Glomerular Deposits in Rats Given Different
Doses ofHeymann Antibody and Treated with Protease
* Significantly less than corresponding control group, p<0.01.
in group D1 (treated during the heterologous phase) on day 11-12, day 15-16,
and days 17-18 were significantly less at all three times (4.5 ± 0.8, 9.8 ± 3.1,
and 5.6 ± 0.8 mg/24 h) than in the group D4 controls (17.6 ± 6.5, 41 .5 ± 14.2,
and 37.6 ± 13.8 mg/24 h; all p values <0.05). Group D3 rats, treated during
the entire period of the autologous phase, also excreted significantly less protein
on day 11-12 (5.0 ± 0.7 mg/24 h), day 15-16 (6.8 ± 1.3 mg/24 h), and day 17-
18 (7.4 ± 2.1 mg/24 h) than group D4 control rats (all p values <0.05). Group
D2 rats, given protease only during the first part of the autologous phase, had
less proteinuria than control rats, but the differences did not attain statistical
significance.
To learn whether protease therapy could reverse proteinuria, we gave treated
rats in group E, which received 40 mg Heymann antibody, protease from day
15, when all rats had significant proteinuria, until day 25 (Fig. 4). Before the
onset of treatment, the rats excreted 13.0 ± 4.1 mg/24 h on day 14-15. A
significant reduction ofproteinuria occurred by 7 d oftreatment, at which time
protease therapy had reduced proteinuria to almost normal values; treated rats
excreted 7.5 ± 1.6 mg/24 h on day 21-22 and 9.4 ± 1.2 mg/24 h on day 24-
25; on the other hand, the untreated controls excreted 12.8 ± 2.1 mg/24 h
(p <0.05) and 17.1 ± 3.3 mg/24 h (p <0.05) at these times.
Antibody Response to Heterologous Protein.
￿
The host serum antibody response
to rabbit IgG after injection of Heymann antibody was measured by ELISA
(Table IV). There were no significant differences between protease-treated and
control animals.
Serum Creatinines.
￿
Among rats given 5, 10, and 60 mg ofHeymann antibody,
the serum creatinine ranged between 0.61 and 0.82 mg/dl, with no significant
differences among subgroups or from age-matched normal rats by analysis of
variance ( F = 0.832).
Possible Adverse Effects of Protease Treatment.
￿
Study by light and electron
microscopy in group F animals (Table 1) revealed no differences between pro-
tease-treated subgroups 1 and 2 vs. control groups 3-6. Therefore, if protease
Animal
group
He mann
antibody
(mg)
Treatment Duration in
days
Length of
glomerular
basement
membrane
examined
(Am)
Number
of electron
dense de-
posits
Number of
deposits per
micrometer of
basement
membrane
A1 5 Enzyme 1-7 477 122 0.256*
2 5 Saline 1-7 234 156 0.667
B1 10 Enzyme 1-5 984 71 0.072*
2 10 Saline 1-5 1,079 222 0.206
CI 10 Enzyme 6-12 1,673 279 0.167*
2 10 Saline 6-12 1,510 510 0.338
D3 60 Enzyme 6-18 1,185 377 0.318*
4 60 - - 883 720 0.8151980 GLOMERULAR IMMUNE COMPLEX AND PROTEINURIA REDUCTION
FIGURE 2.
￿
Electron micrographs from group D rats given 60 mg Heymannantibody on day
1, and killed on day 18 . In rats treated with protease on days 6-18 (A), significantly fewer
electron dense deposits (arrows) are seen in the glomerular basement membrane compared
with untreated controls (B) . BM, basement membrane ; F,p, epithelial podocyte ; En, endothe-
lium . X 21,000 .
altered glomerular structure, any effects on cellular morphology or organization
of the basement membrane were not discernible by microscopy .
We also examined possible induction of proteinuria by administration of
protease to normal rats . Enzyme-treated subgroups F1 and F2 did not manifest
significant proteinuria on day 4-5 or day 11-12 compared with saline-treated
rats (subgroups 3 and 4)and untreated rats (subgroups 5 and 6) (data not shown) .
Protease treatment also had no significant effect on renal function, as reflected
in serum creatinine levels . Among rats in group F, the mean serum creatinines
within the subgroups ranged between 0.19 and 0.55 mg/dl on day 12 ; the least
significant difference forp<0.05, computed from analysis of variance, is 0.75.
No systemic signs of illness were apparent in protease-treated rats, although
we saw 2-3 ml of blood in the intraperitoneal fluid of one-fourth of the killedL
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4-5
￿
11-12 15-16 17-18
Days
FIGURE 3.
￿
24-h protein excretions by group D rats given 60 mg Heymann antibody on day
1 and killed on day 18 are shown over the 18-d course of study. All protease-treated rats
showed numerically less proteinuria than untreated controls (x) at all time points after day 4-
5. These differences were statistically significant (asterisk, p <0.05) in subgroup D1 rats (p),
treated only during the heterologous phase (day 1-7), and in subgroup D3 rats (A) treated
throughout the autologous phase(day 6-18).
10-11 14-15 17-18 21-22 24-25
Days
FIGURE 4.
￿
24-h protein excretions by group E rats given 40 mg Heymann antibody on day
1 and killed on day 25 are shown over the course of study. Protease-treated rats (p) excreted
significantly less protein than controls (x) after a week of treatment (day 21-22), a difference
that wasmaintained until sacrifice (asterisk, p <0 .05).
animals. None of the control animals given enzymes, but not Heymann antibody,
died or appeared ill during the course of the experiments.
Discussion
Membranous nephropathy in humans has a characteristic histopathology in
which granular deposits of IgG and complement are localized along the glomer-1982 GLOMERULAR IMMUNE COMPLEX AND PROTEINURIA REDUCTION
TABLE IV
Serum Antibody Levels AgainstRabbit IgG in Rats Injected
with Heymann Antibody
* Number of animals.
tGroup F includes all subgroups; there were no significant differences among the
subgroups of these nonimmunized rats by analysis of variance (F = 0.907).
ular capillary wall, as determined by immunofluorescence, and exclusively in the
subepithelial space, seen by electron microscopy (18, 19). Autologous immune
complex nephritis and PHN are experimental glomerulonephritides in rats,
initiated when antibody binds to an antigen in the glomerulus. Both models
closely resemble human membranous nephropathy. Autologous immune com-
plex nephritis is induced by immunization with an antigen, Fx 1A, derived from
the brush border of renal proximal tubular epithelial cells; PHN is induced by
heterologous antibody against Fx IA.
Many studies have dealt with the treatment of membranous nephropathy in
humans and experimental models; however, the results have been unsatisfactory
and in many instances controversial. Treatment of the human disease is currently
generally limited to corticosteroids. While proteinuria and nephrotic symptoms
are reduced, the effect of steroids on the ultimate course of the disease remains
unknown. Moreover, the risks of immunosuppression and the other effects of
longterm steroid therapy are well known.
With respect to therapy in the experimental models, while some regimens can
prevent disease, treatment of already established disease has not succeeded (20-
27). Treatment of autologous immune complex nephritis dates from the use of
cortisone, adrenal corticotrophic hormone, and nitrogen mustard by Heymann
et al . in 1962 (20). Corticosteroids and cytotoxic drugs can reduce protein
excretion only if the animals are treated at or before the time of immunization
(21-23). Vasoactive amine antagonists with potent antiserotonin and antihista-
mine activity have either been ineffective or useful only if given before nephritis
(24-27).
In recent years, PHN has been studied more widely than autologous immune
complex nephritis because of its more rapid induction. Feenstra et al. (28) found
that azathioprine was effective in preventing ultrastructural changes and in
reducing protein excretion, again only when started before or simultaneously
with the administration of Heymann antibody . Salant et al. (29) used corticoste-
roids and vasoactive amine blockade; however, neither immune deposits nor
protein excretion were reduced, although they studied only the heterologous
phase. The efficacy of these therapeutic approaches to both autologous immune
complex nephritis and PHN thus appears to lie in suppression of the autologous
Group n* Day of assay ELISA OD ± SE
A1 14 12 0.114 ± 0.018
2 16 12 0.104 ± 0.012
B1 12 5 0.194 ± 0.028
2 12 5 0.256 ± 0.066
Cl. 11 12 0.140 ± 0.021
2 12 12 0.174 ± 0.047
Ft 36 5 or 12 0.081 ± 0.011NAKAZAWA ET AL.
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immuneresponse and/or diminished delivery ofimmune complexes to glomeruli
by virtue of hemodynamic effects, rather than in modulation ofeffector mecha-
nisms or removal of immune deposits. Because such strategies are only prophy-
lactic, they cannot be applied to the therapy of natural glomerulonephritis in
humans or animals.
Lotan etal. (30) reported a significant reduction in proteinuria and glomerular
C3 in PHN after treatment with DMSO, even when treatment began after the
onset of proteinuria. They suggested that DMSO alters the configuration of the
immune deposits and inhibits deposition ofC3.
Since proteinuria occurs in PHN, the efficacy of treatment can be monitored
by measuring urinary protein as well as by assessing glomerular immune deposits
morphologically. Glomerular immune complexes, in sufficient quantity and of
appropriate character, can induce alterations in function, often manifest as
proteinuria; complexes are then said to be nephritogenic. In such cases, deposits
may be so pronounced that morphologic criteria like intensity of immunofluo-
rescence may be insensitive to significant changes in actual amounts of immune
reactants. On theother hand, with lesser, subnephritogenic quantitiesofimmune
reactants, glomerular deposits may still be evident morphologically and yet allow
quantitative differences to be readily appreciated. Since the presence or absence
of glomerular dysfunction appears to reflect the quantity of immune reactants
deposited, morphological evaluation and nephritis measured by altered glomer-
ular performance (e. g., proteinuria) are both useful parameters, but at different
doses of Heymann antibody.
We considered thatproteases might be efficacious in PHN bydirectly digesting
the glomerular immune complexes. In the present work, PHN was induced by
intravenous injection ofHeymann antibody. First, subnephritogenic doses below
the threshold for proteinuria were given. Among rats given 5 mg Heymann
antibody, the minimum dose leading to autologous glomerular immune deposits
observable by immunofluorescence on day 12 (group A), protease treatment was
successful in removing glomerular immune deposits. 10 mg of Heymann anti-
body, the minimum dose permitting identification of rabbit IgG on day 5 in the
heterologous phase, was given in two different experiments (groups B and C).
In group B, animals were treated with enzymes during the entire heterologous
phase (days 1-5), while in group C they were treated during the autologous
phase (days 6-12). We saw significant differences in both intensity and frequency
of heterologous rabbit antibody, as detected by immunofluorescence, between
treated and control rats in group B at the end of the heterologous phase on day
5. When treatment commenced on day 6 (group C), a time when maximal
deposition of rabbit IgG has already occurred (31), immune deposits of both
rabbit and autologous rat IgG were significantly less on day 12. In addition to
results observable by immunofluorescence, the small subepithelial electron dense
deposits typically seen in rats given these amounts of Heymann antibody were
also significantly reduced in number by protease treatment. Together, these
results show thatproteasetreatment canremove immune deposits from glomeruli
in PHN. Since protease treatment did not inhibit the antibody response of the
host to theheterologous rabbit IgG, depressed antibody synthesis canbe excluded
as the explanation for the reduction in immune deposits.1984 GLOMERULAR IMMUNE COMPLEX AND PROTEINURIA REDUCTION
60 mg Heymann antibody, a large nephritogenic dose that can induce protein-
uria, was administered to rats in group D. By immunofluorescence, deposits were
readily noted, and there were no significant differences in rabbit IgG, rat IgG,
or rat C3 between treated and control rats. However, with the larger and more
numerous electron dense deposits that develop at this dose, there were conspic-
uous and statistically significant reductions after protease treatment. In addition,
treatment during the heterologous phase ceasing on day 7 essentially prevented
proteinuria well into the autologous phase. Treatment begun after the heterol-
ogous phase and continued for 6 d reduced but did not eliminate proteinuria;
however, the marked increase in proteinuria observable on days 15-16 and 17-
18 in untreated control rats was completely prevented by continuing enzyme
therapy to day 18. These results suggest that protease is effective not only when
started at the time disease is initiated (heterologous phase), but even when
delayed until the usual time ofonset ofthe autologous phase.
The group E experiment, using 40 mg of Heymann antibody, aimed at
determining whether proteinuria could be reversed by protease therapy. 40 mg
was purposely chosen to produce mild but consistent proteinuria in the autolo-
gous phase. The results showed that enzyme therapy was indeed effective, even
when begun as late as day 15.
We favor the interpretation that protease treatment directly removes glomer-
ular immune deposits and thereby ameliorates proteinuria. The prevention or
reversal of proteinuria by such treatment is not simply due to digestion of
circulating Heymann antibody since immunofluorescence for rabbit IgG was
bright in all kidneys after large doses of Heymann antibody, and levels of host
serum antibody against rabbit IgG were not different in treated and control rats.
We cannot exclude several other less likely possibilities contributing to the
diminished proteinuria. Among these, protease could conceivably change the
conformation of immune deposits, interfere with actionsofthe membrane attack
complex of complement, or act on glomerular cell receptors that are important
in coupling immunologic stimuli to pathophysiological responses. However, none
of these alternative hypotheses can account for the differences in intensity of
immune reactants observed by immunofluorescence or the decreased number
and size ofdeposits seen by electron microscopy.
Overall, the experiments suggest some general potential for the therapeutic
use of proteolytic enzymes in glomerular immune complex disease. We did not
see overt toxicity, and renal function was not compromised. Doubtless, the
regimen can be improved and other enzymes deserve consideration. Additional
studies will be required to investigate the effects ofproteases on various mediator
systems and inflammatory cells relevant to glomerulonephritis.
Summary
We investigated the effect of proteolytic enzyme treatment on the course of
passive Heymann nephritis (PHN). PHN was induced by intravenous injection
of Heymann antibody into Sprague Dawley rats. Protease-treated rats received
intraperitoneal chymopapain and subtilisin. In rats given subnephritogenic doses
of Heymann antibody (5 or 10 mg, insufficient to cause proteinuria), glomerular
immune deposits were assessed by immunofluorescence and electron microscopy.In rats given 5 mg Heymann antibody and treated with protease in the heterol-
ogous phase of the disease (days 1-7), fewer animals were positive for rabbit IgG
and rat IgG, as determined by immunofluorescence on day 12, compared with
controls (p <0.01). Rats given 10 mg Heymann antibody and treated on days 1-
5 were less frequently positive for rabbit IgG on day 5 than controls (p <0.05).
When treatment was given on days 6-12 (autologous phase), fewer rats had
glomerular rabbit and rat IgG compared with controls (p <0.025). Protease
treatment of rats given nephritogenic doses of Heymann antibody (>_40 mg,
causing proteinuria) did not result in significant differences in immunofluores-
cence deposits. However, protease treatment significantly reduced the number
of electron dense deposits at all doses of antibody (p <0 .01). Furthermore, rats
given 60 mg Heymann antibody followed by enzyme treatment in the heterolo-
gous phase (days 1-7) or throughout the autologous phase (days 6-18) had
significantly reduced protein excretion during the autologous phase compared
with control rats (p <0.05). After onset of significant proteinuria on day 15 in
rats given 40 mg Heymann antibody and treated from day 15 until day 25, there
was significantly less (p <0.05) proteinuria on days 21-22 and 24-25 than in
control rats; thus, enzymes could reverse proteinuria. In normal rats, adminis-
tration of proteases did not have significant effects on urinary protein excretion,
serum creatinine, or renal morphology, nor did protease affect anti-rabbit IgG
antibody production in rats injected with Heymann antibody. The overall results
indicate that proteolytic enzyme treatment can prevent or remove glomerular
immune deposits and can prevent or reverse proteinuria.
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